Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Management of recurrent or persistent choroidal neovascularization secondary to age-related macular degeneration
2010-021923-29Phase 2Completed
- Sponsor
- Department of Ophthalmology, Medical University of Vienna
- Start
- Jul 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by Department of Ophthalmology, Medical University of Vienna. Primary endpoints: best-corrected visual acuity and central retinal thickness. Started Jul 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2010-021923-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021923-29.